F
Francis J. Koszyk
Researcher at G. D. Searle & Company
Publications - 32
Citations - 803
Francis J. Koszyk is an academic researcher from G. D. Searle & Company. The author has contributed to research in topics: Alkyl & Trifluoromethyl. The author has an hindex of 13, co-authored 32 publications receiving 800 citations.
Papers
More filters
Patent
Substituted pyrazoles as p38 kinase inhibitors
Anantanarayan Ashok,John E. St. Louis Baldus,Michael Clare,Paul W. Collins,Joyce Z. Crich,Rajesh Ballwin Devraj,Daniel L. Flynn,Lifeng Geng,Matthew J. Graneto,Cathleen E. Hanau,Gunnar J. Hanson,Susan J. Hartmann,Michael St. Charles Hepperle,He Huang,Kevin D. Jerome,Ish K. Khanna,Francis J. Koszyk,Shuyuan Liao,Suzanne Metz,Win Naing,Richard A. Partis,Thao D. Perry,Shashidhar N. Rao,Shaun R. Selness,Michael S. Chesterfield South,Stealey Michael A,John J. Talley,Vazquez Michael L,John K. Walker,Richard M. Weier,Xiangdong Gurnee Xu,Syaulan Chesterfield Yang,Yi Glenview Yu +32 more
TL;DR: A class of pyrazole derivatives described for use in treating p38 kinase mediated disorders are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.
Journal ArticleDOI
1,2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective, and Orally Active Antiinflammatory Agents
Ish K. Khanna,Richard M. Weier,Yu Yi,Xiangdong Xu,Francis J. Koszyk,Paul W. Collins,Carol M. Koboldt,A. W. Veenhuizen,William E. Perkins,Jacquelen J. Casler,Jaime L. Masferrer,Yan Zhang,S. A. Gregory,Karen Seibert,Peter C. Isakson +14 more
TL;DR: Several orally active diarylimidazoles show no GI toxicity in the rat and mouse up to 200 mpk and a study on the influence of substituents in the imidazole ring established that a CF3 group at position 4 gives the optimum oral activity.
Patent
1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
Ish K. Khanna,Richard M. Weier,Paul W. Collins,Yu Yi,Xiangdong Xu,Richard A. Partis,Francis J. Koszyk +6 more
TL;DR: In this article, a class of imidazolyl compounds is described for use in treating inflammation and inflammation-related disorders, and compounds of particular interest are defined by Formula I: ##STR1## wherein R1 -R6 are as described in the specification; or a pharmaceutically acceptable salt thereof.
Patent
2,3-substituted pyridines for the treatment of inflammation
TL;DR: In this paper, a class of substituted pyridyl compounds was described for use in treating inflammation and inflammation-related disorders, and the compounds of particular interest were defined by formula (II), wherein R?5 and R6? are one or more radicals independently selected from halo, alkylsulfonyl, aminosulfonyls, alkoxy and alkylthio.
Patent
Method for treating a mammal infected with respiratory syncytial virus
TL;DR: In this article, a method for treating a mammal infected with respiratory syncytial virus (RSV) comprising administering to the mammal an RSV inhibitory effective amount of a compound or its pharmaceutically acceptable salt of the formula ##STR1## wherein R 1 is alkyl, aralkyl, aroyl or acyl and R 2, R 3, R 4 and R 5 are H or ayl.